DOCSLIB.ORG

(12) United States Patent (10) Patent No.: US 6,391,895 B1 Towart Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) United States Patent (10) Patent No.: US 6,391,895 B1 Towart Et Al USOO639 1895B1 (12) United States Patent (10) Patent No.: US 6,391,895 B1 Towart et al. (45) Date of Patent: May 21, 2002 (54) NITRICOXIDE RELEASING CHELATING FOREIGN PATENT DOCUMENTS AGENTS AND THER THERAPEUTIC USE WO O 292 761 A 11/1988 WO WO 93 20806 A 10/1993 (75) Inventors: Robertson Towart, Stoke Poges (GB); WO WO 95 12394 A 5/1995 Jan Olof Gustav Karlsson, WO WO 96 31217 A 10/1996 Nesoddtangen (NO); Lars Goran WO WO 96 394O9 A 12/1996 Wistrand; Hakan Malmgren, both of WO WO 97.49390 A 12/1997 Lund (SE) WO 97/494.09 12/1997 ................. 514/335 (73) Assignee: Amersham Health AS, Oslo (NO) OTHER PUBLICATIONS (*) Notice: Subject to any disclaimer, the term of this Mooradian D.L. et al., “Nitric Oxide (No) Donor Molecules: patent is extended or adjusted under 35 Effect of No Release Rate on Vascular Smooth Muscle Cell U.S.C. 154(b) by 0 days. Proliferation in Vitro’, Journal of Cardiovascular Pharma cology, Jan. 1, 1995, XP000563583. (21) Appl. No.: 09/599,862 Lefer D.J.: “Myocardial Protective Actions of Nitric Oxide Doors. After Myocardial Ischemia and Reperfusion”, New (22) Filed: Jun. 23, 2000 Horizons, Feb. 1, 1995, XP000575669. Related U.S. Application Data * cited by examiner (63) Continuation of application No. PCT/GB98/03804, filed on Dec. 18, 1998. Primary Examiner-Charanjit S. Aulakh (60) Provisional application No. 60/076.793, filed on Mar. 4, (74) Attorney, Agent, or Firm-Royal N. Ronning, Jr. 1998. (57) ABSTRACT (30) Foreign Application Priority Data Chelating agents, in particular dipyridoxyl and aminopoly Dec. 23, 1997 (GB) ............................................. 9727226 carboxylic acid based chelating agents, and their metal Mar. 13, 1998 (GB) ............................................. 9805450 chelates, when linked directly or indirectly to at least one (51) Int. Cl." ..................... A61K 31/444; CO7D 401/12 nitric oxide releasing moiety, or when use in combination (52) U.S. Cl. ....................... 514/335; 546/261; 546/256; with nitric oxide or a nitric oxide releasing moiety have been 546/255; 546/24; 514/333; 514/332; 514/184 found to be effective in treating a variety of disorders. In (58) Field of Search ................................. 514/335, 333, particular, Such compounds may be used in treating condi 514/332, 184; 546/261, 256, 255, 24 tions associated with the presence of free radicals in the body, e.g. reperfusion injuries, and in reducing the car (56) References Cited diotoxicity of anti-tumor agents, e.g. anthracyclines and/or paclitaxel. U.S. PATENT DOCUMENTS 5,250,550 A 10/1993 Keefer et al. 37 Claims, No Drawings US 6,391,895 B1 1 2 NITRICOXIDE RELEASING CHELATING vascular irregularities as well as hematological and gas AGENTS AND THER THERAPEUTIC USE trointestinal toxicity. Anthracycline antibiotics, Such as doxorubicin This application is a continuation of pending interna (adriamycin), are amongst the most important of the anti tional application number PCT/GB98/03804, filed Dec. 18, tumor agents. However, their clinical value is also limited by 1998, now WO99/33823 (of which the entire disclosure of their cardiotoxicity, which manifests itself as congestive the pending, prior application is hereby incorporated by heart failure in 15-40% of patients undergoing therapy. The reference), which itself is a continuation-in-part of U.S. most likely mechanism for their toxicity is believed to be the provisional application No. 60/076,793, filed Mar. 4, 1998. production of oxygen-derived free radicals in the heart The present invention relates to nitric oxide releasing which cause membrane damage and mitochondrial damage compounds and their use in treating a variety of disorders, in metabolically active tissueS Such as heart muscle and in particular conditions resulting from the presence of free intestinal mucosa. Whilst there is evidence to Suggest that radicals in the body. In particular, the invention relates to the cardiac damage during anthracycline therapy can be reduced use of Such compounds in the treatment of ischaemia-related by Simultaneous administration of the iron chelator, diseases, inflammatory conditions, and retroviral diseases, in 15 deXraZOxane, this has been found to be toxic and as a result anti-tumor therapy, and in cytotoxic antimicrobial treatment can only be used in relatively low dosages. (e.g. to combat bacteria, parasites, etc.). It will be appreciated that there exists a continuing need Short-lived but highly reactive free radicals have long for alternative compounds capable of treating or preventing been believed to be involved in various sorts of tissue conditions generally arising from the presence of free radi damage, especially in ischaemia-related diseaseS Such as cals in the body, in particular compounds which are able to Stroke, cerebral injury and thrombotic diseases, and during prevent reperfusion injuries and act as chemoprotectants reperfusion of ischaemic tissue Such as may occur during during anti-cancer therapy. transplantation or microSurgery. Tissue-damaging free radi In particular, there exists a need for an effective chemo cals may also be produced in certain chronic diseases, for protectant which in reducing the toxic effects of anti-tumor example in diabetes, and are also produced as a result of 25 agents, will permit higher, more effective doses of Such Several anti-cancer treatments, Such as radiation therapy or agents to be administered. treatment with cytotoxic drugs, e.g. anthracyclines or pacli We have now found that chelating agents linked to at taxel (taxol). least one nitric oxide releasing moiety, and their metal Ischaemia-related diseases, in particular coronary artery chelates, are particularly effective in relieving Symptoms diseases, account for the majority of deaths in Western asSociated with reperfusion of ischaemic tissue, and in countries. Typically, coronary narrowing is due to the for reducing the toxicity of anti-tumor agents, e.g. anthracy mation of thromboses at the Site of atherosclerotic plaques. clines and paclitaxel. Acute coronary thrombosis is often treated by agressive It has also been found that certain chelating agents, e.g. thrombolytic treatment with streptokinase or r-tRA with the dipyridoxyl and aminopolycarboxylic acid based chelating object of reperfusing the obstructed artery. However, reoc 35 agents, and their metal chelates, either when linked directly clusion occurs in approx. 10% of cases. Severe coronary or indirectly to at least one nitric oxide releasing moiety, or artery disease can be ameliorated by elective by-pass when used in combination with nitric oxide or a nitric oxide Surgery, with attendant perioperative risks, or in Some releasing moiety, are effective in treating a variety of patients by the mechanical dilation of the blood vessels by disorders, especially conditions associated with the presence angioplasty. However, the latter treatment carries a signifi 40 of free radicals in the body. cant risk (approx. 30–40%) of restenosis within 6 months. Thus, Viewed from one aspect the invention provides the The reintroduction of oxygenated blood into ischaemic use of a chelating agent, or a metal chelate or Salt thereof, cardiac tissue can, in many cases, result in various forms of capable of releasing nitric oxide in Vivo in the manufacture cardiac dysfunction, including arrhythmias, myocardial of a therapeutic agent for use in relieving Symptoms asso “stunning', arterial Spasm and endothelial damage 45 ciated with reperfusion of ischaemic tissue. (Kirschner et al. J. Amer. College of Surgeons 179; 103-117, In another aspect the invention provides a method of 1994). Several studies now suggest that much of this reoxy treatment of the human or non-human animal body to relieve genation damage is a result of the production of Superoxide the Symptoms associated with reperfusion of ischaemic which may in turn lead to intracellular reduction of ferritin tissue, Said method comprising administering to Said body a bound Fe(III) to Fe(II) and lipid peroxidation (see Ryan & 50 chelating agent, or a metal chelate or Salt thereof, capable of Aust, Crit. Rev. Toxicol. 22: 119, 1992). Furthermore, the releasing nitric oxide in Vivo. production of certain free radicals, e.g. Superoxide, can Viewed from a further aspect the invention provides the result in reaction with and hence reduced levels of nitric use of a chelating agent, or a metal chelate or Salt thereof, oxide. This is undesirable since nitric oxide is believed to be capable of releasing nitric oxide in Vivo in the manufacture essential for correct endothelial function (e.g. antithrom 55 of a therapeutic agent for use in reducing the cardiotoxicity botic activity) and for avoiding vasospasm. Nitric oxide is of an anti-tumor agent, e.g. an anthracycline drug and/or also believed to have cardioprotective effects (see Vegh et al. paclitaxel. Brit. J. Pharmacol. 107: 910–911, 1992 and Lefer et al. In another aspect the invention provides a method of Circulation 88: 2337–2350, 1993). reducing the cardiotoxicity of an anti-tumor agent adminis A number of anti-tumor agents are associated with 60 tered to the human or non-human animal body, e.g. a method adverse side-effects which severely limit their widespread of reducing the cardiotoxicity of an anthracycline drug use. Paclitaxel is one Such agent which has shown anti and/or paclitaxel, Said method comprising administering to neoplastic action against a variety of malignant tissues, Said body an anti-tumor agent and Simultaneously, Sepa including those of the breast, colon, lung and ovary, as well rately or Sequentially a chelating agent, or a metal chelate or as in malignant melonoma. However, at the high dosages 65 Salt thereof, capable of releasing nitric oxide in Vivo. required to have an anti-neoplastic effect, paclitaxel has a Viewed from another aspect the invention provides the number of adverse Side-effects which can include cardio use of a chelating agent, or a metal chelate or Salt thereof, US 6,391,895 B1 3 4 capable of releasing nitric oxide in Vivo in the manufacture and EP-A-436579, and analogues and derivatives thereof.
Load more

Recommended publications
  • Tolerance and Resistance to Organic Nitrates in Human Blood Vessels
    \ö-\2- Tolerance and Resistance to Organic Nitrates in Human Blood Vessels Peter Radford Sage MBBS, FRACP Thesis submit.ted for the degree of Doctor of Philosuphy Department of Medicine University of Adelaide and Cardiology Unit The Queen Elizabeth Hospital I Table of Gontents Summary vii Declaration x Acknowledgments xi Abbreviations xil Publications xtil. l.INTRODUCTION l.L Historical Perspective I i.2 Chemical Structure and Available Preparations I 1.3 Cellular/biochemical mechanism of action 2 1.3.1 What is the pharmacologically active moiety? 3 1.3.2 How i.s the active moiety formed? i 4 1.3.3 Which enzyme system(s) is involved in nitrate bioconversi<¡n? 5 1.3.4 What is the role of sulphydryl groups in nitrate action? 9 1.3.5 Cellular mechanism of action after release of the active moiety 11 1.4 Pharmacokinetics t2 1.5 Pharmacological Effects r5 1.5.1 Vascular effects 15 l.5.2Platelet Effects t7 1.5.3 Myocardial effects 18 1.6 Clinical Efhcacy 18 1.6.1 Stable angina pectoris 18 1.6.2 Unstable angina pectoris 2t 1.6.3 Acute myocardial infarction 2l 1.6.4 Congestive Heart Failure 23 ll 1.6.5 Other 24 1.7 Relationship with the endothelium and EDRF 24 1.7.1 EDRF and the endothelium 24 1.7.2 Nitrate-endothelium interactions 2l 1.8 Factors limiting nitrate efficacy' Nitrate tolerance 28 1.8.1 Historical notes 28 1.8.2 Clinical evidence for nitrate tolerance 29 1.8.3 True/cellular nitrate tolerance 31 1.8.3.1 Previous studies 31 | .8.3.2 Postulated mechanisms of true/cellular tolerance JJ 1.8.3.2.1 The "sulphydryl depletion" hypothesis JJ 1.8.3.2.2 Desensitization of guanylate cyclase 35 1 8.i.?..3 Impaired nitrate bioconversion 36 1.8.3.2.4'Ihe "superoxide hypothesis" 38 I.8.3.2.5 Other possible mechanisms 42 1.8.4 Pseudotolerance ; 42 1.8.4.
    [Show full text]
  • Nitric Oxide Releasing Chelating Agents and Their
    Europäisches Patentamt *EP001060174B1* (19) European Patent Office Office européen des brevets (11) EP 1 060 174 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.7: C07D 401/12, A61K 31/44 of the grant of the patent: 22.09.2004 Bulletin 2004/39 (86) International application number: PCT/GB1998/003840 (21) Application number: 98962567.8 (87) International publication number: (22) Date of filing: 18.12.1998 WO 1999/033823 (08.07.1999 Gazette 1999/27) (54) NITRIC OXIDE RELEASING CHELATING AGENTS AND THEIR THERAPEUTIC USE STICKSTOFFOXID FREISETZENDE CHELATBILDNER UND IHRE THERAPEUTISCHE VERWENDUNG CHELATEURS LIBERANT DE L’OXYDE NITRIQUE ET LEUR EMPLOI A DES FINS THERAPEUTIQUES (84) Designated Contracting States: (74) Representative: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU Hammett, Audrey Grace Campbell et al MC NL PT SE Amersham plc Amersham Place (30) Priority: 23.12.1997 GB 9727226 Little Chalfont, Bucks. HP7 9NA (GB) 13.03.1998 GB 9805450 (56) References cited: (43) Date of publication of application: EP-A- 0 292 761 WO-A-93/20806 20.12.2000 Bulletin 2000/51 WO-A-95/12394 WO-A-96/31217 WO-A-96/39409 WO-A-97/49390 (73) Proprietor: Amersham Health AS US-A- 5 250 550 0401 Oslo (NO) • MOORADIAN D L ET AL: "NITRIC OXIDE (NO) (72) Inventors: DONOR MOLECULES: EFFECT OF NO • TOWART, Robertson RELEASE RATE ON VASCULAR SMOOTH Stoke Poges SL2 4PT (GB) MUSCLE CELL PROLIFERATION IN VITRO" • KARLSSON, Jan, Olof, Gustav JOURNAL OF CARDIOVASCULAR N-1450 Nesoddtangen (NO) PHARMACOLOGY, vol.
    [Show full text]
  • Prediction of the Crystalline Densities of Aliphatic Nitrates by Quantum Chemistry Methods
    Central European Journal of Energetic Materials ISSN 1733-7178; e-ISSN 2353-1843 Copyright © 2019 Sieć Badawcza Łukasiewicz – Institute of Industrial Organic Chemistry, Poland Cent. Eur. J. Energ. Mater. 2019, 16(3): 412-432; DOI 10.22211/cejem/112306 Article is available in PDF-format, in colour, at: http://www.wydawnictwa.ipo.waw.pl/cejem/Vol-16-Number3-2019/CEJEM_00978.pdf Article is available under the Creative Commons Attribution-Noncommercial-NoDerivs 3.0 license CC BY-NC-ND 3.0. Research paper Prediction of the Crystalline Densities of Aliphatic Nitrates by Quantum Chemistry Methods Guixiang Wang,* Yimin Xu, Chuang Xue, Zhiyuan Ding, Yan Liu, Hui Liu, Xuedong Gong** Computation Institute for Molecules and Materials, Department of Chemistry, Nanjing University of Science and Technology, Nanjing 210094, China E-mails: * [email protected]; ** [email protected] Abstract: Crystal density is a basic and important parameter for predicting the detonation performance of explosives, and nitrate esters are a type of compound widely used in the military context. In this study, thirty-one aliphatic nitrates were investigated using the density functional theory method (B3LYP) in combination with six basis sets (3-21G, 6-31G, 6-31G*, 6-31G**, 6-311G* and 6-31+G**) and the semiempirical molecular orbital method (PM3). Based on the geometric optimizations at various theoretical levels, the molecular volumes and densities were calculated. Compared with the available experimental data, the densities calculated by various methods are all overestimated, and the errors of the PM3 and B3LYP/3-21G methods are larger than those of other methods. Considering the results and the computer resources required by the calculations, the B3LYP/6-31G* method is recommended for predicting the crystalline densities of organic nitrates using a fitting equation.
    [Show full text]
  • Commerce in Explosives; 2020 Annual Those on the Annual List
    Federal Register / Vol. 85, No. 247 / Wednesday, December 23, 2020 / Notices 83999 inspection at the Office of the Secretary or synonyms in brackets. This list Black powder substitutes. and on EDIS.3 supersedes the List of Explosive *Blasting agents, nitro-carbo-nitrates, This action is taken under the Materials published in the Federal including non-cap sensitive slurry and authority of section 337 of the Tariff Act Register on January 2, 2020 (Docket No. water gel explosives. of 1930, as amended (19 U.S.C. 1337), 2019R–04, 85 FR 128). Blasting caps. and of §§ 201.10 and 210.8(c) of the The 2020 List of Explosive Materials Blasting gelatin. Commission’s Rules of Practice and is a comprehensive list, but is not all- Blasting powder. Procedure (19 CFR 201.10, 210.8(c)). inclusive. The definition of ‘‘explosive BTNEC [bis (trinitroethyl) carbonate]. materials’’ includes ‘‘[e]xplosives, BTNEN [bis (trinitroethyl) nitramine]. By order of the Commission. BTTN [1,2,4 butanetriol trinitrate]. Issued: December 18, 2020. blasting agents, water gels and detonators. Explosive materials, Bulk salutes. William Bishop, include, but are not limited to, all items Butyl tetryl. Supervisory Hearings and Information in the ‘List of Explosive Materials’ Officer. C provided for in § 555.23.’’ 27 CFR Calcium nitrate explosive mixture. [FR Doc. 2020–28458 Filed 12–22–20; 8:45 am] 555.11. Accordingly, the fact that an BILLING CODE 7020–02–P Cellulose hexanitrate explosive explosive material is not on the annual mixture. list does not mean that it is not within Chlorate explosive mixtures. coverage of the law if it otherwise meets DEPARTMENT OF JUSTICE Composition A and variations.
    [Show full text]
  • Federal Register/Vol. 79, No. 194/Tuesday, October 7, 2014
    60496 Federal Register / Vol. 79, No. 194 / Tuesday, October 7, 2014 / Notices Commission rules 210.21(a)(2), (b)(1). DEPARTMENT OF JUSTICE are regulated explosive materials The ALJ also found that there is no regardless of their size or specific indication that termination of the Bureau of Alcohol, Tobacco, Firearms, energetic composition. The addition of investigation in view of the settlement and Explosives this term will not expand the list to agreement would have an adverse [Docket No. 2014R–25T] include any materials not already impact on the public interest. No party covered under other names. ATF petitioned for review of the ID. The Commerce in Explosives; 2014 Annual generally classifies pyrotechnic fuse as Commission has determined not to List of Explosive Materials low explosives subject to the Federal explosives laws and implementing review the ID and has terminated the AGENCY: Bureau of Alcohol, Tobacco, investigation. explosives regulations at 27 CFR Part Firearms, and Explosives (ATF); 555—Commerce in Explosives and the The authority for the Commission’s Department of Justice. U.S. Department of Transportation determination is contained in section ACTION: Notice of list of explosive classifies them as Class 1 explosives. 337 of the Tariff Act of 1930, as materials. External burning pyrotechnic fuses that amended, 19 U.S.C. 1337, and in Part are components of small arms 210 of the Commission’s Rules of SUMMARY: Pursuant to 18 U.S.C. 841(d) ammunition will remain exempt Practice and Procedure, 19 CFR part and 27 CFR 555.23, the Department pursuant to 18 U.S.C.
    [Show full text]
  • Endothelial Dysfunction in Heart Failure and Ischemic Heart Disease: Rationale for the Clinical Use of Mononitrates
    Heart International / Vol. 3 no. 3-4, 2007 / pp. 86-97 © Wichtig Editore, 2007 Endothelial dysfunction in heart failure and ischemic heart disease: rationale for the clinical use of mononitrates OBERDAN PARODI, RENATA DE MARIA, ELÈNA ROUBINA CNR Clinical Physiology Institute of Milan, Cardiology Department, Niguarda Cà Granda Hospital, Milan - Italy ABSTRACT: The clinical observation that heart failure can progress independently of the pa- tient’s hemodynamic status has focused interest on new, potential mechanisms underlying the progression of cardiac insufficiency. It has been shown that in both ischemic and non-ischemic heart failure, endothelial dysfunction and reduced bioavailability of NO can contribute to the process of left ventricular remodelling. The endothelial dysfunction contributes to increasing pe- ripheral vascular resistance, limiting blood flow to skeletal muscles, particularly during exercise, and compromising the regulation of pulmonary blood flow, leading to a flow-perfusion mis- match. The nitroderivates are a heterogeneous class of compounds that have in common their pharmacodynamic action, which is mediated through the production of NO. Isosorbide-2-mononitrate (IS-2-MN) and isosorbide-5-mononitrate (IS-5-MN) are the two main metabolites of isosorbide dinitrate (ISDN) and both act on the smooth muscle cells of vessel walls, causing generalized peripheral vasodilation, which is more marked in the venous system, reduced venous return to the heart and a reduction in peripheral resistance. The shorter half-life of IS-2-MN compared to that of IS-5-MN allows greater fluctuation of the blood levels of the drug; it can, therefore, be hypothesized that tolerance would develop more slowly.
    [Show full text]
  • Characterization and Analysis of Tetranitrate Esters Jimmie C
    Characterization and Analysis of Tetranitrate Esters Jimmie C. Oxley; James, L. Smith; Joseph E. Brady, IV; Austin C. Brown University of Rhode Island, Chemistry Dept; Kingston, RI 02881 Abstract Thermal behaviors, vapor pressures, densities, and drop weight impact results, as well as analytical protocols, are reported for three tetranitrate esters: erythritol tetranitrate (ETN), 1,4‐ dinitrato‐2,3‐dinitro‐2,3bis(nitratomethylene) butane (DNTN), and pentaerythritol tetranitrate (PETN). ETN and DNTN both melt below 100oC and have ambient vapor pressures comparable to TNT. While LC/MS was shown to be a viable technique for analysis of all three tetranitrate esters, only ETN was successfully analyzed by GC/MS. Performance of these nitrate esters as evaluated in lab using the small-scale explosivity device (SSED) suggested RDX >> DNTN > PETN > ETN. Detonation velocities were calculated using Cheetah 6.0. Since the starting material is now widely available, it is likely that law enforcement will find ETN in future improvised explosive devices. This paper with its analytical schemes should prove useful in identification of this homemade explosive. Keywords: erythritol tetranitrate, ETN, 1,4‐dinitrato‐2,3‐dinitro‐2,3bis(nitratomethylene) butane, DNTN, pentaerythritol tetranitrate, PETN, vapor pressure, densities, drop weight impact, thermal behavior, HPLC‐HRMS 1. Introduction In recent years there has been growth in use of so-called “homemade” explosives (HME). Preparation of HME can require little synthetic expertise. It can be as simple as mixing oxidizers and fuels as opposed to the preparation and isolation of discrete compounds. When specific characteristics are required terrorists do engage in more complex synthetic procedures.
    [Show full text]
  • Characterization of Explosives & Precursors
    Appendix A: Project Reports ALERT Thrust R1: Characterization & Elimination of Illicit Explosives Phase 2 Year 4 Annual Report Project R1-A.1 R1-A.1: Characterization of Explosives & Precursors I. PARTICIPANTS Faculty/Staff Name Title Institution Email Jimmie Oxley Co-PI URI [email protected] Jim Smith Co-PI URI [email protected] Gerald Kagan Post-Doc URI [email protected] Graduate, Undergraduate and REU Students Name Degree Pursued Institution Month/Year of Graduation Matt Porter PhD URI 5/2017 Austin Brown PhD URI 5/2017 Kevin Colizza PhD URI 5/2018 Lindsay McLennan PhD URI 5/2018 Devon Swanson PhD URI 5/2017 Jamie Butalewich BS URI 5/2021 II. PROJECT DESCRIPTION A. Project Overview All new materials require characterization. In the case of explosives, complete characterization is a matter of safety as well as performance. Most homemade explosives (HMEs) are not new, with some having been reported in the late 1800s. However, common handling of these explosives and resulting accidents caused by those involved in the homeland security enterprise (HSE) demand a thorough understanding of their proper- ties. Admittedly, this mission is too big to cover without more researchers, funding, and time. Therefore, we have chosen areas considered most urgent or reachable by our present experience and instrument capabil- ities. We have examined triacetone triperoxide (TATP) in detail. Presently, we are examining hexamethylene triperoxide diamine (HMTD), erythritol tetranitrate (ETN), and other nitrated sugars and fuel/oxidizer (FOX) mixtures. Characterization has included a detailed study of the thermal decomposition of ETN. Our work has highlight- ed a hazardous operation that many in the HSE perform.
    [Show full text]
  • Explosive Properties of Melt Cast Erythritol Tetranitrate (ETN)
    Central European Journal of Energetic Materials ISSN 1733-7178; e-ISSN 2353-1843 Copyright © 2017 Institute of Industrial Organic Chemistry, Poland Cent. Eur. J. Energ. Mater. 2017, 14(2): 418-429 DOI: 10.22211/cejem/68471 Explosive Properties of Melt Cast Erythritol Tetranitrate (ETN) Martin Künzel,* Robert Matyáš, Ondřej Vodochodský, Jiri Pachman Institute of Energetic Materials, Faculty of Chemical Technology, University of Pardubice, Studentska 95, Pardubice, 532 10, Czech Republic *E-mail: [email protected] Abstract: Erythritol tetranitrate (ETN) is a low melting, solid, nitrate ester with significant explosive properties. The increased availability of its precursor (erythritol), which is now used as a sweetener, has attracted attention to the possible misuse of ETN as an improvised explosive. However, ETN also has some potential to be used as a component of military explosives or propellants. This article focuses on the properties of melt-cast ETN. The sensitivity of the compound towards impact and friction was tested. The explosive performance was evaluated, based on cylinder expansion tests and detonation velocity measurements. The impact energy and friction force required for 50% probability of initiation was 3.79 J and 47.7 N, respectively. A Gurney velocity value of G = 2771 m·s−1 and a detonation velocity of 8027 m·s−1 at a charge density of 1.700 g·cm−3, were found for the melt-cast material. The sensitivity characteristics of melt-cast ETN does not differ significantly from either literature values or the authors’ data measured using the crystalline material. The explosive performance properties were found to be close to those of PETN.
    [Show full text]
  • Quantifying the Stability of Trace Explosives Under Different
    Talanta 165 (2017) 10–17 Contents lists available at ScienceDirect Talanta journal homepage: www.elsevier.com/locate/talanta ff Quantifying the stability of trace explosives under di erent environmental MARK conditions using electrospray ionization mass spectrometry☆ ⁎ Edward Siscoa, , Marcela Najarroa, Daniel Samarovb,Jeffrey Lawrencea a National Institute of Standards and Technology, Materials Measurement Science Division, Gaithersburg, MD, USA b National Institute of Standards and Technology, Statistical Engineering Division, Gaithersburg, MD, USA ARTICLE INFO ABSTRACT Keywords: This work investigates the stability of trace (tens of nanograms) deposits of six explosives: erythritol tetranitrate Trace explosives (ETN), pentaerythritol tetranitrate (PETN), cyclotrimethylenetrinitramine (RDX), cyclotetramethylenetetrani- Mass spectrometry tramine (HMX), 2,4,6-trinitrotoluene (TNT), and 2,4,6-trinitrophenylmethylnitramine (tetryl) to determine Degradation environmental stabilities and lifetimes of trace level materials. Explosives were inkjet printed directly onto Environmental stability substrates and exposed to one of seven environmental conditions (Laboratory, −4 °C, 30 °C, 47 °C, 90% relative humidity, UV light, and ozone) up to 42 days. Throughout the study, samples were extracted and quantified using electrospray ionization mass spectrometry (ESI-MS) to determine the stability of the explosive as a function of time and environmental exposure. Statistical models were then fit to the data and used for pairwise comparisons of the environments. Stability was found to be exposure and compound dependent with minimal sample losses observed for HMX, RDX, and PETN while substantial and rapid losses were observed in all conditions except −4 °C for ETN and TNT and in all conditions for tetryl. The results of this work highlight the potential fate of explosive traces when exposed to various environments.
    [Show full text]
  • Organic Chemistry of Explosives
    JWBK121-FM October 11, 2006 21:10 Char Count= 0 Organic Chemistry of Explosives Dr. Jai Prakash Agrawal CChem FRSC (UK) Former Director of Materials Defence R&D Organisation DRDO House, New Delhi, India email: [email protected] Dr. Robert Dale Hodgson Consultant Organic Chemist, Syntech Chemical Consultancy, Morecambe, Lancashire, UK Website: http://www.syntechconsultancy.co.uk email: [email protected] iii JWBK121-FM October 11, 2006 21:10 Char Count= 0 iii JWBK121-FM October 11, 2006 21:10 Char Count= 0 Organic Chemistry of Explosives i JWBK121-FM October 11, 2006 21:10 Char Count= 0 ii JWBK121-FM October 11, 2006 21:10 Char Count= 0 Organic Chemistry of Explosives Dr. Jai Prakash Agrawal CChem FRSC (UK) Former Director of Materials Defence R&D Organisation DRDO House, New Delhi, India email: [email protected] Dr. Robert Dale Hodgson Consultant Organic Chemist, Syntech Chemical Consultancy, Morecambe, Lancashire, UK Website: http://www.syntechconsultancy.co.uk email: [email protected] iii JWBK121-FM October 11, 2006 21:10 Char Count= 0 Copyright C 2007 John Wiley & Sons Ltd, The Atrium, Southern Gate, Chichester, West Sussex PO19 8SQ, England Telephone (+44) 1243 779777 Email (for orders and customer service enquiries): [email protected] Visit our Home Page on www.wiley.com All Rights Reserved. No part of this publication may be reproduced, stored in a retrieval system or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning or otherwise, except under the terms of the Copyright, Designs and Patents Act 1988 or under the terms of a licence issued by the Copyright Licensing Agency Ltd, 90 Tottenham Court Road, London W1T 4LP, UK, without the permission in writing of the Publisher.
    [Show full text]
  • Possible Modes of Cytotoxicity of High Energy Aliphatic Nitroesters and N-Nitramines for Mouse Splenocytes
    CHEMIJA. 2012. Vol. 23. No. 2. P. 141–146 © Lietuvos mokslų akademija, 2012 Possible modes of cytotoxicity of high energy aliphatic nitroesters and N-nitramines for mouse splenocytes Valė Miliukienė, In this work, we report for the first time the cytotoxicity data of a large number of struc- turally diverse high energy aliphatic nitrate esters and N-nitramines (n = 20) to mouse Jonas Šarlauskas, splenocyte cells. Their concentrations causing 50% cell death (cL50) vary from 18 µM (N-nitro-diethanolamine dinitrate) to >250 µM (octahydro-1,3,5,7-tetranitro-1,3,5,7- Kastis Krikštopaitis, tetrazocine, ethylene glycol dinitrate). The log cL50 of compounds does not depend on the calculated heats of their hydride adduct formation, or voltammetric reduction peak poten- Algirdas Šaikūnas, tials, or lipophilicity. The cytotoxicity of compounds is not oxidative stress-dependent. On the other hand, their cytotoxicity is partly decreased by an inhibitor of aldehyde dehydro- Narimantas Čėnas* genase (EC 1.2.1.10), tetraethylthiuram disulfide. It shows an involvement of this enzyme in bioreductive activation of nitrate esters and N-nitramines with the liberation of nitrite, Institute of Biochemistry which is further converted to NO. of Vilnius University, Mokslininkų 12, Key words: organic nitrate ester, N-nitramine, cytotoxicity, aldehyde dehydrogenase LT-08662 Vilnius, Lithuania Abbreviations: cL50 – compound concentration causing 50% cell death, ∆Hf – heat of for- mation, Ep(7) – voltammetric reduction peak potential at pH 7.0, P – octanol / water partition coefficient, GTN – glycerol trinitrate, PETN – pentaerythritol tetranitrate, RDX – hexahy- dro-1,3,5-trinitro-1,3,5-triazine, HMX – octahydro-1,3,5,7-tetranitro-1,3,5,7-tetrazocine, TNT – 2,4,6-trinitrotoluene, P-450R – NADPH: cytochrome P-450 reductase, ADH – alde- hyde dehydrogenase.
    [Show full text]